Clinical investigation of efficacy and safety of iron supplement in pregnant women affected by iron deficiency anemia. - Nil

Generex Pharmassist Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年8月21日

试验速览

暂无简介。

•1. Pregnant females with age between 18-40 years (Both inclusive) 2. Presence of a live, singleton, intrauterine fetus and dating ultrasound at screening that indicates a pregnancy that would be between week 13 to week 20 (both inclusive) 3. Female with primi or multigravida 4. Pregnant females without any other comorbidity 5. Hemoglobin levels between 9-10.5 gm/dl (Bothinclusive) 6. With or without the fatigue associated with anemia 7. Serum ferritin levels between 10-15 mcg/L (Both inclusive) 8. Able to give written informed consent 9. Able to follow up through visits.

•1.Pregnant women of less than 13 weeks and more than 20 of gestation;2.Pregnant female with complicated pregnancy history or ongoing treatment for the same;3.Pregnant women with complications like bleeding piles, excessive emesis, active peptic ulcer, diabetes, hypertension, eclampsia, hypothyroidism and hyperthyroidism and multiple pregnancy;4.Fetal anomaly if detectable when an initial ultrasound is done to date the pregnancy;
•5.Subjects on any concomitant therapy for treating IDA during study period 6.Not willing to provide consent or follow up; 7.Any condition from investigator viewpoint can affect patient participation in the study.

发起方